We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GENRUI BIOTECH INC.

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
04 May 2021 - 07 May 2021
Virtual Venue

CSF Biomarker Flags Parkinson's Pathology Much Earlier

By LabMedica International staff writers
Posted on 16 Mar 2021
Print article
Image: In-vitro misfolded α-synuclein amplification by real-time quaking-induced conversion (Photo courtesy of University of Edinburgh).
Image: In-vitro misfolded α-synuclein amplification by real-time quaking-induced conversion (Photo courtesy of University of Edinburgh).
Isolated rapid-eye-movement (REM) sleep behavior disorder (IRBD) can be part of the prodromal stage of the α-synucleinopathies Parkinson's disease and dementia with Lewy bodies years before clinical symptoms appear.

Real-time quaking-induced conversion (RT-QuIC) analysis of cerebrospinal fluid (CSF) has high sensitivity and specificity for the detection of misfolded α-synuclein in patients with Parkinson's disease and dementia with Lewy bodies.

An international team of Neuroscientists working with the University of Edinburgh (Edinburgh, UK) obtained CSF samples by lumbar puncture from patients with video polysomnography-confirmed IRBD recruited at a specialized sleep disorders center in Barcelona, Spain, and from controls free of neurological disease. There were 52 patients with IRBD and 40 healthy controls matched for age, sex and duration of follow-up underwent lumbar puncture between March 23, 2008, and July 16, 2017. CSF samples were stored until analyzed using RT-QuIC.

The team reported that during follow-up, 32 patients (62%) were diagnosed with Parkinson's disease or dementia with Lewy bodies a mean 3.4 years after lumbar puncture, of whom 31 (97%) were α-synuclein positive at baseline. Specifically, 16 people developed Parkinson's (15 of whom were positive for CSF α -synuclein), and 16 developed dementia with Lewy bodies (all were positive for CSF α-synuclein). CSF α-synuclein RT-¬QuIC was positive in 47 (90%) of 52 patients and in four (10%) of 40 healthy controls, resulting in a sensitivity of 90.4% (95% CI 79.4–95.8) and a specificity of 90.0% (95% CI 76.9–96.0).

The average interval for people who were alpha-synuclein positive at baseline to convert to clinically defined Parkinson's or dementia with Lewy bodies was 3.2 years. Patients with IRBD who were α-synuclein negative had lower risk for developing Parkinson's disease or dementia with Lewy bodies at 2, 4, 6, 8, and 10 years of follow-up than patients with IRBD who were α-synuclein positive. During follow-up, none of the controls developed an α-synucleinopathy.

Alison Green, PhD, a Reader in Biochemistry and a senior author of the study, said, “The detection of pathological α-synuclein preceded the development of clinical symptoms by a mean of 3.2 years, with a range of 6 months to 9 years. This is the first step towards having a reliable biomarker for early, pre-symptomatic disease which will enable therapeutic interventions, including potential neuroprotective treatments, to start in a timelier manner.”

The authors concluded that in patients with IRBD, RT-QuIC detects misfolded α-synuclein in the CSF with both sensitivity and specificity of 90%, and α-synuclein positivity was associated with increased risk of subsequent diagnosis of Parkinson's disease or dementia with Lewy bodies. Detection of α-synuclein in the CSF represents a potential prodromal marker of Parkinson's disease and dementia with Lewy bodies. The study was published on March 1, 2021 in the journal Lancet Neurology.


Related Links:
University of Edinburgh

Gold Supplier
COVID-19 ELISA Test
COVID-19 ELISA
COVID-19 Anitibody Test
TGS COVID-19 IgG
New
Gold Supplier
SARS-CoV-2, Flu A/B, and RSV Test
SARS-CoV-2 PLUS ELITe MGB Kit
New
Silver Supplier
COVID-19 Ag Rapid Test
COVID-19 Ag Rapid Test Kit

Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: The EZ DNA Methylation-Direct Kit (Photo courtesy of Zymo Research)

Leukocyte Epigenomics and Artificial Intelligence Predict Late-Onset Alzheimer’s Disease

Alzheimer’s Disease (AD) is the most common form of age-related dementia, accounting for 60%–80% of such cases. The disorder causes a wide range of significant mental and physical disabilities, with profound... Read more

Industry

view channel
Image: The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing (Photo courtesy of Mobidiag Ltd.)

Hologic to Acquire Mobidiag to Strengthen Diagnostic Testing Business

Hologic, Inc. (Marlborough, MA, USA) has signed a definitive agreement to acquire Mobidiag Ltd. (Espoo, Finland) in a USD 795 million transaction that will accelerate the global growth of Mobidiag’s differentiated... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.